We are excited to announce that Eagle IP will be returning as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Spring conference in Boston. Our President and Managing Director, Ms. Jennifer Che, is one of the distinguished speakers at the event. Organized by Life Sciences Intellectual Property Review, this event will take place on May 6-7, 2025, at the Hyatt Regency Boston located at One Avenue de Lafayette, Boston, MA 02111.

Come join us there and meet us at our booth!

Every year, LSPN brings together experts from pharmaceutical, biotech, and medtech industries to discuss innovation and IP protections. The conference covers patentability, eligibility, prosecution, and litigation, offering insights for the entire patent protection lifecycle in the US.

For more information about the conference and to complete your registration, please visit: https://www.lspnnorthamerica.com

If you won’t be able to attend LSPN but will be in Boston and would like to schedule a meeting, please let us know. We would be happy to arrange a convenient time to connect.

We are looking forward to seeing you in Boston!

我们的过去活动

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

2025年11月26日

Jennifer Che has been Recognized as IAM Global Leaders 2026

2025年11月4日

Eagle IP is Coming to San Francisco and Washington DC!

2025年10月15日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Recommended Insights

A More Detailed Overview of China’s Patent Term Extension (PTE) System

2024年6月17日
Although PTE has been in the Chinese Patent Law since the 4th Amendment of the law came into effect June 1, 2021, we didn’t really know the exact details of how it operated until the Implementation Regulations and Examination Guidelines (“Implementation Regulations”) were finally released in December 2023. New Rules 77-84 in the Implementation Regulations […]
阅读更多 >

Everything you need to know about Patent Term Adjustment (PTA) in China

2024年5月7日
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
阅读更多 >

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
阅读更多 >

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
阅读更多 >
Top crossarrow-right